-+ 0.00%
-+ 0.00%
-+ 0.00%

Mizuho Maintains Outperform on ADMA Biologics, Lowers Price Target to $17

Benzinga·07/15/2026 18:20:08
语音播报
Mizuho analyst Anthony Petrone maintains ADMA Biologics (NASDAQ:ADMA) with a Outperform and lowers the price target from $20 to $17.